Sheridan K. Snedden
62 IP cases indexed. Covers patent matters.
Cases Presided Over
62 cases indexed | Page 1 of 3
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed Corp. successfully convinced the PTAB to institute IPR proceedings against Cleveland Medical Devices regarding a patent covering sleep disorder treatment/CPAP systems. The Board found that ResMed demonstrated a reasonable likelihood of prevailing on Grounds 1-3, which centered on obviousness (35 U.S.C. § 103).
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed Corp. successfully challenged Cleveland Medical Devices' sleep apnea monitoring patent via IPR, arguing the claims were obvious over combinations of prior art references. The Board found a reasonable likelihood of prevailing on at least one claim, leading to institution.
Guardant Health, Inc. v.Cold Spring Harbor Laboratory
Guardant Health’s IPR against the ’013 single‑cell sequencing patent resulted in the Board finding all 28 claims unpatentable as obvious over prior publications by Linnarsson and McCloskey. The petition’s obviousness arguments were accepted and the patent owner’s defenses were rejected.
Guardant Health, Inc. v.Cold Spring Harbor Laboratory
Guardant Health’s IPR resulted in all 28 claims of the 10,697,013 B1 patent being held unpatentable for obviousness over prior‑art tagging methods. The Board affirmed the petitioner’s combination of Linnarsson and McCloskey references.
SeaSpine Holdings Corporation et al. v.Jackson, Roger
The PTAB denied an IPR petition filed by SeaSpine Holdings against Roger P. Jackson because the patent owner had disclaimed all challenged claims of U.S. Patent No. 11,399,873 B2.
Intas Pharmaceuticals, Ltd. et al. v.Atossa Therapeutics, Inc.
Court decision.
Intas Pharmaceuticals, Ltd. et al. v.Atossa Therapeutics, Inc.
Intas Pharmaceuticals successfully secured the institution of IPR against Atossa Therapeutics over a drug polymorph patent (11,261,151), challenging claims based on anticipation and obviousness using prior art Liu.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully convinced the PTAB that multiple claims of Helsinn Healthcare's anti-emetic patent were unpatentable. The Board granted institution based on obviousness (103) over several prior art references, paving the way for a full trial.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully petitioned to institute IPR against Helsinn Healthcare's '515 patent covering anti-emetic agents. The Board found a reasonable likelihood of prevailing based on obviousness (103) and prior art, allowing the challenge to proceed.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully petitioned to institute IPR proceedings against Helsinn Healthcare S.A.'s anti-emetic patent (8623826). The Board found a reasonable likelihood of prevailing on independent claim 19, allowing the challenge based on obviousness over prior art like MASCC and Hoffmann.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
Curio Bioscience, Inc.'s IPR challenge against Prognosys and 10X Genomics was denied by the PTAB. The Board found that Petitioner failed to demonstrate a reasonable likelihood of prevailing on grounds of obviousness (over Cantor/Armani) and anticipation (by Frisen).
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR challenge against Prognosys and 10X Genomics, finding that the asserted claims were not obvious or anticipated by the prior art. The Board specifically rejected arguments linking Cantor to spatial analysis in tissue sections.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR against Prognosys/10X Genomics, finding no grounds for invalidity based on obviousness (Cantor/Armani) or anticipation (Frisen). The Board concluded that the prior art did not teach the necessary combination elements of spatially encoded biological assays.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR challenge against Prognosys and 10X Genomics, finding no reasonable likelihood of prevailing on grounds of anticipation (102), obviousness (103), or written description (112). The Board upheld the validity of the challenged claims in spatial omics/assay systems technology.
ResMed Corp. v.Cleveland Medical Devices, Inc.
The PTAB denied ResMed Corp.'s Inter Partes Review petition against Cleveland Medical Devices' patent, citing prior filings and concerns over 'road-mapping'.
Curio Bioscience et al. v.Prognosys Biosciences Inc. et al.
The PTAB denied the IPR petition brought by Curio Bioscience against Prognosys and 10X Genomics, finding that the challenged claims were not obvious over Cantor or anticipated by Frisen. The Board upheld the Patent Owner's position regarding spatial analysis in tissue samples.
Dr. Squatch, LLC v.The Procter & Gamble Company
Dr. Squatch successfully petitioned the PTAB to challenge The Procter & Gamble Company's deodorant patent (11844752). The Board granted institution on all 19 claims, finding sufficient evidence of obviousness over various prior art combinations. This sets up a major trial regarding the validity of P&G’s core cosmetic technology.
Dr. Squatch, LLC v.The Procter & Gamble Company
The PTAB found all 19 challenged claims unpatentable based on obviousness (35 U.S.C. § 103). The Petitioner successfully demonstrated that a Person Having Ordinary Skill in the Art would have been motivated to combine various prior art references for predictable results. This decision confirms the validity of the combination approach under POSA principles in deodorant formulation technology.
Jeisys Medical Inc. et al. v.Serendia, LLC
EndyMed Medical and Serendia settled their inter partes review disputes over U.S. Patent 9,775,774, leading the PTAB to terminate the proceedings and keep the settlement confidential.
Jeisys Medical Inc. et al. v.Serendia, LLC
The PTAB granted a settlement‑based termination for Jeisys Medical in three IPRs while allowing the proceedings to continue for EndyMed. The settlement agreement was ordered to be kept confidential.
Jeisys Medical Inc. et al. v.Serendia, LLC
The PTAB instituted an IPR challenging claims 13 and 14 of Serendia's patent, finding a reasonable likelihood of anticipation by the prior art reference Mehta. The case moves to trial phase after rejecting arguments for discretionary denial based on competitor relationships.
EndyMed Medical Ltd. et al. v.Serendia, LLC
EndyMed Medical and Serendia reached a settlement that resolved all disputes over U.S. Patent No. 10,869,812. The Board granted a joint motion to terminate the instituted IPRs and treated the settlement agreement as confidential business information.
Jeisys Medical Inc. et al. v.Serendia, LLC
Serendia and Jeisys Medical settled their IPR dispute over U.S. Patent 9,320,536, leading the PTAB to terminate the proceeding.
Jeisys Medical Inc. et al. v.Serendia, LLC
The PTAB instituted the IPR challenge against Serendia's '536 patent, finding a reasonable likelihood of unpatentability. The Board determined that prior art (Mehta) discloses the claimed depth control feature despite arguments for fixed-length needles.
3D Diagnostix, Inc. v.Watson Guide IP, LLC
3D Diagnostix successfully petitioned to institute IPR against Watson Guide IP regarding dental prosthesis claims under 103. The Board found sufficient evidence of obviousness, despite disputes over claim language and prior art interpretation.
3D Diagnostix, Inc. v.Watson Guide IP, LLC
The PTAB found that all challenged claims were obvious over various combinations of prior art references, including Llop '126 and Sichuan. The Board determined there was a clear motivation for a person skilled in the art to combine these references to achieve the claimed invention.
Dr. Squatch, LLC v.The Procter & Gamble Company
The PTAB decided to institute IPR proceedings against a deodorant/antiperspirant patent, finding that Petitioner demonstrated a reasonable likelihood of prevailing on several key claims. The decision validates the use of multiple prior art references in personal care compositions for obviousness challenges.
Dr. Squatch, LLC v.The Procter & Gamble Company
Dr. Squatch, LLC successfully challenged The Procter & Gamble Company's patent claims in an IPR proceeding, demonstrating a reasonable likelihood of prevailing on unpatentability for key deodorant compositions. The Board found that prior art references taught sufficient motivation to combine elements across different personal care fields.
Dr. Squatch, LLC v.The Procter & Gamble Company
The PTAB issued a final written decision finding all 23 challenged claims of U.S. Patent No. 11,497,706 unpatentable. The petitioner successfully demonstrated that the claimed aluminum-free deodorant compositions were anticipated or rendered obvious by various combinations of prior art references.
Dr. Squatch, LLC v.The Procter & Gamble Company
The PTAB found that the petitioner's challenges against claims 1-7, 9-13, and 16-19 were successful. The Board determined that the challenged deodorant formulations were unpatentable under both 35 U.S.C. § 102 (anticipation) and § 103 (obviousness).
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.